©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Aug 15, 2019; 10(8): 421-445
Published online Aug 15, 2019. doi: 10.4239/wjd.v10.i8.421
Published online Aug 15, 2019. doi: 10.4239/wjd.v10.i8.421
Bone health in diabetes and prediabetes
Silvia Costantini, Caterina Conte, Department of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University, Milan 20123, Italy
Silvia Costantini, Epatocentro Ticino, Lugano 6900, Switzerland
Caterina Conte, IRCCS Ospedale San Raffaele, Internal Medicine and Transplantation, Milan 20123, Italy
Author contributions: Both authors equally contributed to this paper with conception and design of the article, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: No potential conflicts of interest to declare.
Corresponding author: Caterina Conte, MD, PhD, Assistant Professor, Department of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University, via Olgettina 60, Milan 20123, Italy. conte.caterina@unisr.it
Telephone: +39-2-36432575
Received: April 6, 2019
Peer-review started: April 8, 2019
First decision: May 9, 2019
Revised: June 3, 2019
Accepted: July 20, 2019
Article in press: July 20, 2019
Published online: August 15, 2019
Processing time: 132 Days and 17.6 Hours
Peer-review started: April 8, 2019
First decision: May 9, 2019
Revised: June 3, 2019
Accepted: July 20, 2019
Article in press: July 20, 2019
Published online: August 15, 2019
Processing time: 132 Days and 17.6 Hours
Core Tip
Core tip: Diabetes mellitus, either type 1 or type 2, is associated with increased fracture risk. Diabetic hyperglycemia and insulin resistance underlie functional alterations of bone cells and bone marrow fat that affect several determinants of bone strength, including bone matrix proteins and bone mass, geometry and microarchitecture. Diabetes-related microvascular complications and certain antidiabetic drugs appear to further increase fracture risk, both directly and indirectly. The prevention and management of bone fragility in diabetes includes identification of patients at risk, correction of modifiable risk factors including appropriate choice of antidiabetic drugs and use of antifracture drugs with proven efficacy.